Genetic Technologies Limited · ASX:GTG
Genetic Technologies — H1 FY2022 Earnings Presentation
34 slides from Genetic Technologies's earnings presentation, Feb 25, 2022
Slide 1: GeneType Presentation Half Year Update
For personal use only GeneType Presentation Half Year Update February 24, 2022 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: Notice: Forward looking statements
For personal use only Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they
Slide 3: Our Overview
Our Overview For personal use only Our Vision and Values Our Channels & Divisions Unlocking personalised preventative health Segmentation and distribution channels Our Markets & Global Presence Our Portfolio & Innovation Expansion to over 40 countries Cutting edge technology & ‘game changing’ partne
Slide 4: Genetype Vision
For personal use only Genetype Vision 4
Slide 5: Unlocking personalised preventative health
Unlocking personalised For personal use only preventative health Our Mission Transform the conversation, transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information, they need to manage their health according to their own risk. B
Slide 6: Patented integrated risk testing for a range of serious conditions
Patented integrated risk testing for a range For personal use only of serious conditions. Genetype tests integrate individual’s familial, clinical and genetic information into actionable clinical insights. Combining genetic and clinical risk models with cutting-edge research, we’re leading a persona
Slide 7: Global Overview
Global Overview For personal use only 54 40 27 Employees Countries Patents globally Granted (9 Pending) 14 51 12 Test Tests Partner Categories Laboratories 7 7
Slide 8: Key Geographies and Collaborators
Key Geographies and Collaborators For personal use only Genetype and EasyDNA Established in 40 countries with 12 established partnerships United States Europe & UK Asia Australia & New (Inc. SEA, China and India) Zealand geneType® Polygenic Risk EasyDNA available in EasyDNA available in Certificatio
Slide 9: Our Brand Values
Our Brand Values For personal use only Unequalled experience Leading integrated technology Scientific team leveraging their extensive The proprietary integration of genomic and research track record in breast and clinical risk factors deliver the most colorectal to expand our medical-grade complete
Slide 10: Our Focus
Our Focus For personal use only Commercialisation of the geneType suite of multi-tests EasyDNA Growth: New Test. New Channels. New Markets. Demonstration of clinical validity & clinical utility of geneType tests Bolster commercial bias to our OPEX Our 6 Talent & capability acquisition Big Plays Inno
Slide 11: Market Size and Opportunity
Market Size and Opportunity Estimated Global Revenue growth is USD$2.8B in to 2025 For personal use only CAGR 16.3% Predictive Genomics1 Growth $1.3B Direct to Consumer2 CAGR 18.1% Growth $1.4B 2.01 2025 0.76 2.60 2020 1.22 USD ($B) USD ($B’m) 1. Newsire - Predictive Genetics Market Research Report
Slide 12: Pathways to Market
Pathways to Market For personal use only Direct to Consumer Consumer initiated Medical Business to Testing (DTC) testing (CIT) Business (B2B) with no medical supervision with medical supervision Revenue Leveraging the EasyDNA Brand and Health Economic modeling being Drivers Building consumer Awarene
Slide 13: Pathways to Market
Pathways to Market Executing a multi-brand strategy For personal use only 1 Direct to consumer [insert revenue structure and agreement Ancestry Animaltypes] Paternity Drug testing Product list Health & Wellbeing Relationship Pharmacogenetics Covid- Antigen Tests* Consumer-initiated testing 2 ± teleh
Slide 14: Our Innovation
For personal use only Our Innovation Product Overview 14 14
Slide 15: Our Innovation - Multi Test
Our Innovation - Multi Test A companion diagnostic PRS to help identify risk of serious For personal use only disease for up to 70% of Mortalities and Morbidities GeneType Multi- test to include >70% of mortality Diseases Areas & morbidity Oncology Cardiovascular Breast Cancer Atrial Fibrillation Co
Slide 16: NEW: Patented Covid Risk Test (US)
NEW: Patented1 Covid Risk Test (US) For personal use only https://genetype.com/for-individuals/covid-19 The link goes directly to Vitagene: https://vitagene.com/products/covid-19- risk-test/ Campaign Insights – January 2022 • 32,360 relevant consumer groups across US with 112k impressions over 3 wee
Slide 17: Divisions of Operations
Divisions of Operations For personal use only NEW Existing divisions Universal Pharmoco- collection test kit Oncology Genetics & Emerging divisions BC, CRC, PC, Taliaz to support Multi Melanoma Companion Test Launch diagnostics Germline CVD testing (Heart Disease) BRCA, Lynch IHD, AF Syndrome and So
Slide 18: GeneType Portfolio Timeline
GeneType Portfolio Timeline For personal use only ` ` CIT Platform in AUS Moderate and USA selling BRC Revenue and CRC CY 2021 COVID Risk Test Relaunched with released for sale Vitagene December 2021 with IBX Multi Test to provide Phase 1 - Market Release • Breast Cancer risk assessment for • Colore
Slide 19: Science and Innovation
Science and Innovation Integrated personalised risk assessment For personal use only geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk 1,2
Slide 20: Key Operating Insights
For personal use only Key Operating Insights 20 20
Slide 21: Delivering Revenue and Growth
Delivering Revenue and Growth For personal use only Revenue3 (A$'000) REVENUE CASH BALANCE $2,050 AUD $2.05m AUD $13.5m half-year ending December 31, 2021 GROSS MARGIN GROSS MARGIN $16 H1 FY21 H1 FY22 AUD $855k 41.7% Strategic & Operational Highlights • Post period end, GTG received accreditation fr
Slide 22: Marketing Performance
Marketing Performance For personal use only Digital Brand Performance (Last Month) 115,710 2,816 BRAND IMPRESSIONS (+197%) CLICKS: ADS + SOCIAL (+186%) 2,846 9,032 SOCIAL MEDIA ENGAGEMENTS (+200%) WEBSITE VISITS (+64%) Lead Generation (Last Month) 113 3 19 61 CONTACT FORM HCP PARTNERSHIP NEWSLETTER
Slide 23: Growth strategy for EasyDNA
Growth strategy for EasyDNA For personal use only PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and [insert revenue structure and agreement types] Brand Refreshagreement types] Website Refresh Improved Lead Gen New Sales Channels Product list Product list Multi
Slide 24: 2021 Snapshot and Achievements
2021 Snapshot and Achievements For personal use only Signed multi-year distribution Acquired revenue generating Focused on R&D collaborations agreement platform and Innovation ✓ License and distribution agreement for ✓ Acquired EasyDNA for US$4m ✓ African American Breast Cancer Research COVID-19 Ris
Slide 25: Summary
For personal use only Summary 25
Slide 26: Summary
Summary For personal use only Commercialisation of the geneType suite of multi-tests EasyDNA Growth: New Test. New Channels. New Markets. Demonstration of clinical validity & clinical utility of geneType tests Bolster commercial bias to our OPEX Our 6 Talent & capability acquisition Big Plays Innova
Slide 27: Thank you
For personal use only Thank you Investor Relations - AUS Stephanie Ottens Market Eye +61 434 405 400 stephanie.ottens@marketeye.com.au 27
Slide 28: Appendices
For personal use only Appendices 28
Slide 29: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 23 February 2022 0.5c Other, 23% ADR price (USD) as at 23 February 2022 $1.91 Ord Shares on Issue (M) 9,234 Boa
Slide 30: Financial Overview
Financial Overview For personal use only • Cash burn of A$2.2 million in Q2 FY’22 (compared to Q1 FY’22: A$1.9 million) as we continue to grow EasyDNA brand sales and develop and commercialize our geneType tests A$’000 30 Sep 2021 31 Dec 2021 Change • Cash reserves of A$13.5 million after EasyDNA ac
Slide 31: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Non – Executive FGIA, FTIA, F Fin Executive Director Director Non – Executive Director Dr. Jerzy “George
Slide 32: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, MWGO is Principal Fellow and Reg
Slide 33: Our Intellectual Property
Our Intellectual Property For personal use only 8 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection • Methods for breast cancer risk • Patent 11,031,098, Computer systems and methods for
Slide 34: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score
Genetic Technologies — H1 FY2022 Earnings Presentation on 6ix